Many of the hopeful predictions outlined in the AML summary of 2016 are now therapeutic realities: GO, venetoclax, FLT3 inhibitors (midostaurin, gilteritib), IDH inhibitors (ivosidenib, enasidenib), CPX-351, glasdegib, oral decitabine, and oral azacitidine. Here, IDH2 is linked to acute myeloid leukemia.